ETF盘中资讯｜港股医药再调整，港股通医疗ETF（159137）、港股通创新药ETF（520880）跌2%！低吸时机到了？场内持续溢价！

Market Overview - The Hong Kong stock market experienced a broad adjustment on January 19, with the Hang Seng Index falling nearly 1% and the pharmaceutical sector declining alongside the market [1] - The Hong Kong Stock Connect Medical ETF, Huabao (159137), saw a drop of 2%, frequently trading at a premium, while major stocks like WuXi Biologics fell over 5% [1][2] - AI healthcare leaders JD Health and Alibaba Health both dropped more than 1% [1] Pharmaceutical Sector Performance - The medical sector opened lower and continued to decline, with the Hong Kong Stock Connect Innovation Drug ETF (520880) dropping over 2% during the session [1] - Key stocks in the innovation drug sector, such as BeiGene and CanSino Biologics, also fell by more than 2%, while several others, including China Biologic Products and 3SBio, dropped over 4% [1] Trading Activity - The Hong Kong Stock Connect Innovation Drug ETF (520880) was noted for its persistent premium trading, indicating strong buying interest, with a transaction volume exceeding 200 million yuan [3] - The ETF's price was reported at 0.541, down 1.99%, with a trading volume of 4.65 billion [4] Future Outlook - The National Medical Products Administration of China announced that by 2025, 76 innovative drugs are expected to be approved, placing China at the forefront globally [4] - The total transaction volume for overseas licensing of Chinese innovative drugs is projected to exceed 130 billion USD in the same year [4] - Analysts believe that the Chinese innovative drug sector is entering a phase of simultaneous benefits from "going global, technology, and policy," leading to a revaluation of innovative drug stocks [5] Investment Opportunities - Starting in January 2026, several innovative drug companies will release their earnings forecasts for 2025, presenting potential valuation recovery opportunities for those exceeding expectations [6] - The Hong Kong Stock Connect Innovation Drug ETF (520880) and its associated funds track the Hang Seng Hong Kong Stock Connect Innovation Drug Select Index, which has distinct advantages, including a focus on pure innovative drug companies and a significant weighting of leading firms [6][7] - The top ten innovative drug leaders account for over 73% of the index, highlighting the strength of the sector [7]